US5214066A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for producing an animal model for inflammatory bowel disease including ulcerative colitis
Assignee: The Brigham and Women's Hospital Inc
•
Filing: 1990-04-18
•
Granted: 1993-05-25
•
Expires: 2010-04-18
Abstract
Abstract A new animal model for Inflammatory Bowel Disease, including idiopathic ulcerative colitis and Chron's disease, as well as methods for problems such as an animal, is provided. Chronic ulcerative condition is induced by topical administration of a sulfhydryl blocker, such as N-ethylmaleimide or iodoacetamide, to the colon. The new animal model is useful for studying the pathogenesis of chronic ulcerative disease, and prevention and treatment thereof, and for evaluating drugs suspected of being useful in the treatment of same.
Inventors
- 👤 Sandor Szabo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 07:37
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/185; A61K31/19; A61K31/33; A61K31/395; A61K31/40
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
55 words
A method to produce mammalian idiopathic inflammatory bowel disease in a non-primate laboratory animal comprising topically administering to the colonic mucosa of the laboratory animal a composition comprising a sulfhydryl blocker in an amount effective to produce colonic lesions in said laboratory animal whereby the mammalian idopathic inflammatory bowel disease is produced in the animal.
Claim 2
Independent Claim
55 words
A method to produce mammalian idiopathic inflammatory bowel disease in a non-primate laboratory animal comprising topically administering to the colonic mucosa of the laboratory animal a composition comprising a sulfhydryl blocker in an amount effective to produce colonic lesions in said laboratory animal whereby the mammalian idopathic inflammatory bowel disease is produced in the animal.
Claim 3
Dependent Claim
21 words
The method of claim 1, wherein said sulfhydryl blocker is chosen from the group consisting of N-ethylmaleimide, iodoacetamide, iodoacetate or chloroacetate.
Claim 4
Dependent Claim
14 words
The method of claim 1, wherein said composition further comprises a pharmaceutically effective carrier.
Claim 5
Dependent Claim
11 words
The method of claim 3, wherein said carrier is methyl cellulose.
Claim 6
Dependent Claim
17 words
The method of claim 1 wherein said idiopathic Inflammatory Bowel Disease is ulcerative colitis or Crohn's disease.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-24 | 1996-11-23 | 1997-05-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-24 | 2000-11-23 | 2001-05-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-24 | 2004-11-23 | 2005-05-25 | $7700.00 | Window Closed / Lapsed |